Price T Rowe Associates Inc Karyopharm Therapeutics Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 64,300 shares of KPTI stock, worth $434,025. This represents 0.0% of its overall portfolio holdings.
Number of Shares
64,300
Previous 134,700
52.26%
Holding current value
$434,025
Previous $112,000
60.71%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding KPTI
# of Institutions
94Shares Held
59.6MCall Options Held
547KPut Options Held
67K-
Vanguard Group Inc Valley Forge, PA7.65MShares$51.7 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.32MShares$42.7 Million0.01% of portfolio
-
Palo Alto Investors LP Palo Alto, CA4.91MShares$33.1 Million0.53% of portfolio
-
Black Rock Inc. New York, NY4.17MShares$28.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.51MShares$23.7 Million0.0% of portfolio
About Karyopharm Therapeutics Inc.
- Ticker KPTI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,806,600
- Market Cap $539M
- Description
- Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...